BioXcel Therapeutics
BTAI
74 hedge funds and large institutions have $12.5M invested in BioXcel Therapeutics in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 21 closing their positions.
1% more funds holding
Funds holding: 73 → 74 (+1)
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
5% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 20
0.09% less ownership
Funds ownership: 1.72% → 1.63% (-0.09%)
52% less capital invested
Capital invested by funds: $26.1M → $12.5M (-$13.6M)
54% less call options, than puts
Call options by funds: $159K | Put options by funds: $346K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.47M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$526K |
| 3 |
Jane Street
New York
|
+$262K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$174K |
| 5 |
Millennium Management
New York
|
+$162K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.86M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.63M |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$851K |
| 4 |
State Street
Boston,
Massachusetts
|
-$712K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$605K |
BTAI Hedge Fund Activity: Q2 2024 in Review
74 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2024, worth a combined $12.5M — down 52% from $26.1M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new BTAI positions and 21 closed out — a net gain of 2 holders — while 21 added to existing stakes and 20 trimmed.
The largest buyer was Armistice Capital, adding an estimated $5.47M. The largest seller was BlackRock, cutting an estimated $1.86M.
- 74 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2024, up from 73 in Q1 2024.
- Funds reported $12.5M of BioXcel Therapeutics stock for Q2 2024, down 52% quarter-over-quarter.
- 23 funds opened new BioXcel Therapeutics positions in Q2 2024 and 21 closed out, a net change of +2 holders.
- The largest BioXcel Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $5.47M added.
- The largest BioXcel Therapeutics seller in Q2 2024 was BlackRock, an estimated $1.86M sold.
Based on aggregated 13F filings for Q2 2024.